![Myeloma Paper of the Day, September 6th, suggested by Robert Orlowski](https://oncodaily.com/pub/uploads/2024/09/IMG_20240906_180410_240-1280x720.jpg)
Myeloma Paper of the Day, September 6th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Study of cancer incidence data from SEER22 cancer registry database with 10,183,928 total cases (2000-2020) finds young women have a faster average annual percentage change in myeloma vs. males.”
Source: Robert Orlowski/X
Cancer incidence (2000–2020) among individuals under 35: an emerging sex disparity in oncology
Authors: Alessandro Cavazzani, Claudia Angelini, Dario Gregori and Luca Cardone.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023